Is Zevra Therapeutics, Inc. (ZVRA) a Buy, Sell, or Hold?
NASDAQ : ZVRA
Zevra Therapeutics, Inc.
$12.6792 USD
-$0.28 (-2.17%)
- Volume
- 612.22K
- Average Volume
- 1.69M
- Market Capitalization
- $749.53M
- P/E Ratio
- 5.82
- Dividend Yield
- 0.00%
- Price Target
- $29.00
- Year High
- $15.04
- Year Low
- $7.16
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $4.89
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Neil F. McFarlane |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | ZVRA |
| CUSIP | 488445206 |
| CIK | 0001434647 |
| Web | https://zevra.com |
| Phone | 321 939 3416 |
| Currency | USD |
| Employees | 61 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.01 |
| Payout Ratio | 0.00 |
| Current Ratio | 4.89 |
| Quick Ratio | 4.84 |
| Cash Ratio | 2.03 |
Sales & Book Value
| Annual Sales | $106.47M |
| Price / Sales | 6.13 |
| Cash Flow | 0.21 |
| Price / Cash Flow | 62.49 |
| Price / Book | 3.60 |
Price Target and Rating
| Average Stock Price Forecast | $29.00 |
| High Stock Price Forecast | $35.00 |
| Low Stock Price Forecast | $29.00 |
| Forecast Upside/Downside | -56.28% |
| Consensus Rating | Buy |
| Rating Score(0-5) | 4 |
| Research Coverage | 10 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $1.35 |
| Trailing P/E Ratio | 5.82 |
| PEG Ratio | 0.00 |
| P/E Growth | 0.00 |
| Net Income | $83.23M |
| Net Margin | 101.58% |
| Pretax Margin | 109.09% |
| Return on Equity | 81.34% |
| Return on Assets | 44.59% |
Financials Score
| AltmanZ Score | 7.29 |
| Piotroski Score | 7.00 |
| Working Capital | 182.94M |
| Total Assets | 278.58M |
| Ebit | 137.7M |
| Market Cap | 772.04M |
| Total Liabilities | 72.78M |
Poll Results
About Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Stock
Zevra Therapeutics, Inc., founded in 2006 and based in Celebration, Florida, is a biopharmaceutical company dedicated to discovering and developing innovative treatments for rare diseases. The company employs its proprietary Ligand Activated Therapy (LAT) technology to create novel prodrug versions of existing FDA-approved medications or to enable new applications for other compounds, primarily addressing serious medical conditions within the United States. Zevra's development pipeline is strategically concentrated on high-unmet-need therapeutic areas, including attention deficit hyperactivity disorder (ADHD), stimulant use disorder, and various rare central nervous system (CNS) conditions, such as idiopathic hypersomnia (IH). Their lead product candidate, KP1077, which is a prodrug of d-m ... ethylphenidate (known as serdexmethylphenidate), is currently in Phase II clinical trials for the treatment of both IH and narcolepsy. Another key prodrug candidate, KP879, is also advancing through Phase II studies for stimulant use disorder. In addition to its pipeline, Zevra has successfully secured FDA approval for two products: AZSTARYS, a once-daily treatment for ADHD in patients aged six years and older, and APADAZ, an immediate-release combination product containing benzhydrocodone (a prodrug of hydrocodone) and acetaminophen. The company's product portfolio also includes arimoclomol, and it holds collaboration and licensing agreements with KVK-Tech, Inc. and Commave Therapeutics SA. Formerly known as KemPharm, Inc., the company officially rebranded to Zevra Therapeutics, Inc. in February 2023.
2026-06-23 07:30:00
Data published in Molecular Genetics and Metabolism Reports suggest MIPLYFFA (arimoclomol) was well tolerated in pediatric patients with no new safety signals observed Data published in Molecular Genetics and Metabolism Reports suggest MIPLYFFA (arimoclomol) was well tolerated in pediatric patients with no new safety signals observed
Zevra's Chief Medical Officer to Step Down for Personal Reasons as Part of Planned Transition
2026-06-11 08:30:00
BOSTON, June 11, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases, announced today that its Chief Medical Officer (“CMO”) Adrian Quartel, M.D., FFPM, will be stepping down from his position due to personal reasons, effective July 3, 2026. Dr. Quartel will continue to support Zevra in a consulting capacity through December 31, 2026, while the Company conducts a search for its next CMO and ensures a seamless transition.
2026-06-08 07:30:00
MIPLYFFA patent submitted for Orange Book listing, with patent protection to 2041 Separately filed patent term extension remains pending with the U.S. Patent and Trademark Office BOSTON, June 08, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases, today announced that it has submitted U.S. Patent No. 11,707,456 for MIPLYFFA® (arimoclomol) to the U.S. Food and Drug Administration for listing in the publication Approved Drug Products With Therapeutic Equivalence Evaluations, commonly known as the Orange Book.
Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2026-05-29 16:30:00
BOSTON, May 29, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases, today announced that the Company has granted options to purchase an aggregate of 33,000 shares of the Company's common stock (the “Inducement Awards”) to four new employees pursuant to the Company's 2023 Employment Inducement Award Plan. Each Inducement Award vests over four years, with 25% vesting on the first anniversary of the employee's start date, and the remainder vesting in three equal annual installments thereafter (subject to each such employee's continued employment on each vesting date).
Zevra Therapeutics to Present at the H.C. Wainwright BioConnect Investor Conference
2026-05-12 07:30:00
BOSTON, May 12, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that members of Zevra's executive leadership team will present at the H.C. Wainwright BioConnect Investor Conference in New York, NY on Tuesday, May 19, 2026, at 9:00 a.m. ET.
Zevra Therapeutics to Present at the H.C. Wainwright BioConnect Investor Conference
2026-05-12 07:30:00
BOSTON, May 12, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that members of Zevra's executive leadership team will present at the H.
Zevra Therapeutics, Inc. (ZVRA) Q1 2026 Earnings Call Transcript
2026-05-07 00:21:13
Zevra Therapeutics, Inc. (ZVRA) Q1 2026 Earnings Call Transcript
Zevra Therapeutics (ZVRA) Q1 Earnings and Revenues Surpass Estimates
2026-05-06 19:35:39
Zevra Therapeutics (ZVRA) came out with quarterly earnings of $0.18 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to a loss of $0.06 per share a year ago.
Frequently Asked Questions
-
What is the current Zevra Therapeutics, Inc. (ZVRA) stock price?
-
Zevra Therapeutics, Inc.(NASDAQ:ZVRA) stock price is $12.6792 in the last trading session. During the trading session, ZVRA stock reached the peak price of $15.035 while $7.16 was the lowest point it dropped to. The percentage change in ZVRA stock occurred in the recent session was --2.17% while the dollar amount for the price change in ZVRA stock was -$0.28.
-
ZVRA's industry and sector of operation?
-
The NASDAQ listed ZVRA is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of ZVRA?
-
Adrian Quartel FFPM | Consultant
Rahsaan W. Thompson | Chief Legal Officer, Secretary & Compliance Officer
Timothy J. Sangiovanni | Senior VP of Finance & Corporate Controller
Joshua Schafer | Chief Commercial Officer
Neil F. McFarlane | President, Chief Executive Officer & Director -
How many employees does ZVRA have?
-
Number of ZVRA employees currently stands at 61. ZVRA operates from 1180 Celebration Boulevard, Celebration, FL 34747, US.
-
Link for ZVRA official website?
-
Official Website of ZVRA is: https://zevra.com
-
How do I contact ZVRA?
-
ZVRA could be contacted at phone #321 939 3416 and can also be accessed through its website. ZVRA operates from 1180 Celebration Boulevard, Celebration, FL 34747, US.
-
How many shares of ZVRA are traded daily?
-
The average number of ZVRA shares traded daily for last 3 months was 1.69M.
-
What is the market cap of ZVRA currently?
-
The market value of ZVRA currently stands at $749.53M with its latest stock price at $12.6792